Minicircles: the Next Generation of Plasmids Produce Your Own Minicircles with the MC-Easy Minicircle Production Kit the Develop
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Gibson Assembly Cloning Guide, Second Edition
Gibson Assembly® CLONING GUIDE 2ND EDITION RESTRICTION DIGESTFREE, SEAMLESS CLONING Applications, tools, and protocols for the Gibson Assembly® method: • Single Insert • Multiple Inserts • Site-Directed Mutagenesis #DNAMYWAY sgidna.com/gibson-assembly Foreword Contents Foreword The Gibson Assembly method has been an integral part of our work at Synthetic Genomics, Inc. and the J. Craig Venter Institute (JCVI) for nearly a decade, enabling us to synthesize a complete bacterial genome in 2008, create the first synthetic cell in 2010, and generate a minimal bacterial genome in 2016. These studies form the framework for basic research in understanding the fundamental principles of cellular function and the precise function of essential genes. Additionally, synthetic cells can potentially be harnessed for commercial applications which could offer great benefits to society through the renewable and sustainable production of therapeutics, biofuels, and biobased textiles. In 2004, JCVI had embarked on a quest to synthesize genome-sized DNA and needed to develop the tools to make this possible. When I first learned that JCVI was attempting to create a synthetic cell, I truly understood the significance and reached out to Hamilton (Ham) Smith, who leads the Synthetic Biology Group at JCVI. I joined Ham’s team as a postdoctoral fellow and the development of Gibson Assembly began as I started investigating methods that would allow overlapping DNA fragments to be assembled toward the goal of generating genome- sized DNA. Over time, we had multiple methods in place for assembling DNA molecules by in vitro recombination, including the method that would later come to be known as Gibson Assembly. -
BIOPHYSICS MEETS GENE THERAPY: HOW EXPLORING SUPERCOILING-DEPENDENT STRUCTURAL CHANGES in DNA LED to the DEVELOPMENT of MINIVECTOR DNA Lynn Zechiedrich and Jonathan M
Technology and Innovation, Vol. 20, pp. 427-440, 2019 ISSN 1949-821 • E-ISSN 1949-825X http:// Printed in the USA. All rights reserved. dx.doi.org/10.21300/20.4.2019.427 Copyright © 2019 National Academy of Inventors. www.technologyandinnovation.org BIOPHYSICS MEETS GENE THERAPY: HOW EXPLORING SUPERCOILING-DEPENDENT STRUCTURAL CHANGES IN DNA LED TO THE DEVELOPMENT OF MINIVECTOR DNA Lynn Zechiedrich and Jonathan M. Fogg Department of Molecular Virology and Microbiology, Verna and Marrs McLean Department of Biochemistry and Molecular Biology, and Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA Supercoiling affects every aspect of DNA function (replication, transcription, repair, recom- bination, etc.), yet the vast majority of studies on DNA and crystal structures of the molecule utilize short linear duplex DNA, which cannot be supercoiled. To study how supercoiling drives DNA biology, we developed and patented methods to make milligram quantities of tiny supercoiled circles of DNA called minicircles. We used a collaborative and multidisciplinary approach, including computational simulations (both atomistic and coarse-grained), biochem- ical experimentation, and biophysical methods to study these minicircles. By determining the three-dimensional conformations of individual supercoiled DNA minicircles, we revealed the structural diversity of supercoiled DNA and its highly dynamic nature. We uncovered profound structural changes, including sequence-specific base-flipping (where the DNA base flips out into the solvent), bending, and denaturing in negatively supercoiled minicircles. Counterintuitively, exposed DNA bases emerged in the positively supercoiled minicircles, which may result from inside-out DNA (Pauling-like, or “P-DNA”). These structural changes strongly influence how enzymes interact with or act on DNA. -
Minicircle DNA and Mc-Ips Cells Cat. #SC301A-1, SRMXXXPA-1
Minicircle DNA and mc-iPS Cells Cat. #SC301A-1, SRMXXXPA-1 User Manual A limited-use label license covers this product. By use of this product, you accept the terms and conditions outlined in the Licensing and Warranty Statement ver. 2-111910 contained in this user manual. Minicircle DNA and mc-iPS Cells Cats. # SC301A-1, SRMXXXPA-1 Contents I. Introduction and Background .................................................. 2 A. The Minicircle Technology .................................................. 2 B. Minicircle derived iPS cell line ............................................ 3 II. Protocols ................................................................................. 5 A. Minicircle Production .......................................................... 5 B. Transfection of Minicircle DNA for reprogramming............. 7 C. Growing mc-iPS cells in Feeder-Free Media ...................... 8 III. References........................................................................ 10 IV. Technical Support ............................................................. 11 V. Licensing and Warranty ........................................................ 11 888-266-5066 (Toll Free) 650-968-2200 (outside US) Page 1 System Biosciences (SBI) User Manual I. Introduction and Background A. The Minicircle Technology Minicircles (MC) are circular non-viral DNA elements that are generated by an intramolecular (cis-) recombination from a parental plasmid (PP) mediated by ФC31 integrase. The full-size MC-DNA construct is grown in a special host -
The Transgenic Core Facility
Genetic modification of the mouse Ben Davies Wellcome Trust Centre for Human Genetics Genetically modified mouse models • The genome projects have provided us only with a catalogue of genes - little is know regarding gene function • Associations between disease and genes and their variants are being found yet the biological significance of the association is frequently unclear • Genetically modified mouse models provides a powerful method of assaying gene function in the whole organism Sequence Information Human Mutation Gene of Interest Mouse Model Reverse Genetics Phenotype Gene Function How to study gene function Human patients: • Patients with gene mutations can help us understand gene function • Human’s don’t make particularly willing experimental organisms • An observational science and not an experimental one • Genetic make-up of humans is highly variable • Difficult to pin-point the gene responsible for the disease in the first place Mouse patients: • Full ability to manipulate the genome experimentally • Easy to maintain in the laboratory – breeding cycle is approximately 2 months • Mouse and human genomes are similar in size, structure and gene complement • Most human genes have murine counterparts • Mutations that cause disease in human gene, generally produce comparable phentoypes when mutated in mouse • Mice have genes that are not represented in other model organisms e.g. C. elegans, Drosophila – genes of the immune system What can I do with my gene of interest • Gain of function – Overexpression of a gene of interest “Transgenic -
Stable Episomes Based on Non-Integrative Lentiviral Vectors
(19) TZZ _T (11) EP 2 878 674 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.06.2015 Bulletin 2015/23 C12N 15/86 (2006.01) (21) Application number: 13382481.3 (22) Date of filing: 28.11.2013 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Ramírez Martínez, Juan Carlos GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO E-28029 Madrid (ES) PL PT RO RS SE SI SK SM TR • Torres Ruiz, Raúl Designated Extension States: E-28029 Madrid (ES) BA ME • García Torralba, Aida E-28029 Madrid (ES) (71) Applicant: Fundación Centro Nacional de Investigaciones (74) Representative: ABG Patentes, S.L. Cardiovasculares Carlos III (CNIC) Avenida de Burgos, 16D 28029 Madrid (ES) Edificio Euromor 28036 Madrid (ES) (54) Stable episomes based on non-integrative lentiviral vectors (57) The invention relates to non-intregrative lentivi- the use of these vectors for the production of recombinant ral vectors and their use for the stable transgenesis of lentiviruses, and the use of these recombinant lentivirus- both dividing and no- dividing eukaryotic cells. The inven- es for obtaining a cell able to stably produce a product tion also provides methods for obtaining these vectors, of interest. EP 2 878 674 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 878 674 A1 Description FIELD OF THE INVENTION 5 [0001] The present invention falls within the field of eukaryotic cell transgenesis and, more specifically, relates to episomes based on non-integrative lentiviral vectors and their use for the generation of cell lines that stably express a heterologous gene of interest. -
Review on Applications of Genetic Engineering and Cloning in Farm Animals
Journal of Dairy & Veterinary Sciences ISSN: 2573-2196 Review Article Dairy and Vet Sci J Volume 4 Issue 1 - October 2017 Copyright © All rights are reserved by Ayalew Negash DOI: 10.19080/JDVS.2017.04.555629 Review on Applications of Genetic Engineering And Cloning in Farm animals Eyachew Ayana1, Gizachew Fentahun2, Ayalew Negash3*, Fentahun Mitku1, Mebrie Zemene3 and Fikre Zeru4 1Candidate of Veterinary medicine, University of Gondar, Ethiopia 2Candidate of Veterinary medicine, Samara University, Ethiopia 3Lecturer at University of Gondar, University of Gondar, Ethiopia 4Samara University, Ethiopia Submission: July 10, 2017; Published: October 02, 2017 *Corresponding author: Ayalew Negash, Lecturer at University of Gondar, College of Veterinary Medicine and science, University of Gondar, P.O. 196, Gondar, Ethiopia, Email: Abstract Genetic engineering involves producing transgenic animal’s models by using different techniques such as exogenous pronuclear DNA highly applicable and crucial technology which involves increasing animal production and productivity, increases animal disease resistance andmicroinjection biomedical in application. zygotes, injection Cloning ofinvolves genetically the production modified embryonicof animals thatstem are cells genetically into blastocysts identical and to theretrovirus donor nucleus.mediated The gene most transfer. commonly It is applied and recent technique is somatic cell nuclear transfer in which the nucleus from body cell is transferred to an egg cell to create an embryo that is virtually identical to the donor nucleus. There are different applications of cloning which includes: rapid multiplication of desired livestock, and post-natal viabilities. Beside to this Food safety, animal welfare, public and social acceptance and religious institutions are the most common animal conservation and research model. -
Schematic and Time Line for the Generation of Knockout Mice Aurora Burds Connor, Feb 2007
Schematic and Time Line for the Generation of Knockout Mice Aurora Burds Connor, Feb 2007 Making the DNA construct Time Line (in your lab) The Transgenic Facility also has a “Beginner’s Guide to Gene Targeting” on the website in Methods. We are also happy to assist with advice and reagents to help you make an effective targeting construct. It is recommended that you contact Aurora ([email protected]) early in the process. Acquire the genomic DNA for your gene or locus of interest You can either screen a 129/Sv genomic library 1-3 months or use genomic databases, public BACs and PCR for a C57BL/6 background Make a DNA construct. DNA from the genomic locus (orange) flanks the DNA to be inserted (blue) and it is placed in a bacterial plasmid. This construct is designed to add new pieces of DNA into the mouse genome at a 3-6 months desired locus. In a knockout experiment, the new DNA will replace the normal gene. Linearize the construct and give it to the Rippel ES Cell Facility at MIT Generating Targeted ES Cells Time Line (done by the Facility) Day 0 Insert the DNA into embryonic stem cells (ES cells) via electroporation. In the cells, the homologous pieces of DNA recombine. This inserts new DNA from the construct into the desired locus, usually replacing a portion of the original genome. Place the ES cells in selective media, allowing for the growth of cells containing the DNA construct. - The DNA construct has a drug-resistance marker Day 1-10 - Very few of the cells take up the construct – cells that do not will die because they are not resistant to the drug added to the media. -
Minicircle DNA Technology
Minicircle DNA Technology MNxxxx-1 User Manual Please see PAC for storage temperatures A limited-use label license covers this product. By use of this product, you accept Version 7 the terms and conditions outlined in the 5/30/2017 License and Warranty Statement contained in this user manual. Contents Product Description ...................................................................................................................................................... 1 Minicircle Technology ............................................................................................................................................... 1 ZYCY10P3S2T E.coli ................................................................................................................................................... 2 List of Components ....................................................................................................................................................... 2 Storage .......................................................................................................................................................................... 2 Protocols ....................................................................................................................................................................... 2 cDNA Cloning into Minicircle Parental Plasmids ...................................................................................................... 2 Cloning into Minicircle shRNA Parental Plasmids .................................................................................................... -
The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases
International Journal of Molecular Sciences Review The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases Lyes Toualbi 1,2, Maria Toms 1,2 and Mariya Moosajee 1,2,3,4,* 1 UCL Institute of Ophthalmology, London EC1V 9EL, UK; [email protected] (L.T.); [email protected] (M.T.) 2 The Francis Crick Institute, London NW1 1AT, UK 3 Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK 4 Great Ormond Street Hospital for Children NHS Found Trust, London WC1N 3JH, UK * Correspondence: [email protected]; Tel.: +44-207-608-6971 Abstract: Inherited retinal diseases (IRDs) are a heterogeneous group of disorders causing progres- sive loss of vision, affecting approximately one in 1000 people worldwide. Gene augmentation therapy, which typically involves using adeno-associated viral vectors for delivery of healthy gene copies to affected tissues, has shown great promise as a strategy for the treatment of IRDs. How- ever, the use of viruses is associated with several limitations, including harmful immune responses, genome integration, and limited gene carrying capacity. Here, we review the advances in non-viral gene augmentation strategies, such as the use of plasmids with minimal bacterial backbones and scaffold/matrix attachment region (S/MAR) sequences, that have the capability to overcome these weaknesses by accommodating genes of any size and maintaining episomal transgene expression with a lower risk of eliciting an immune response. Low retinal transfection rates remain a limita- tion, but various strategies, including coupling the DNA with different types of chemical vehicles (nanoparticles) and the use of electrical methods such as iontophoresis and electrotransfection to aid Citation: Toualbi, L.; Toms, M.; Moosajee, M. -
Production of Lentiviral Vectors Using Novel, Enzymatically Produced, Linear DNA
Gene Therapy (2019) 26:86–92 https://doi.org/10.1038/s41434-018-0056-1 ARTICLE Production of lentiviral vectors using novel, enzymatically produced, linear DNA 1 2,3 4 4 4 Rajvinder Karda ● John R. Counsell ● Kinga Karbowniczek ● Lisa J. Caproni ● John P. Tite ● Simon N. Waddington1,5 Received: 17 October 2018 / Revised: 27 November 2018 / Accepted: 5 December 2018 / Published online: 14 January 2019 © The Author(s) 2019. This article is published with open access Abstract The manufacture of large quantities of high-quality DNA is a major bottleneck in the production of viral vectors for gene therapy. Touchlight Genetics has developed a proprietary abiological technology that addresses the major issues in commercial DNA supply. The technology uses ‘rolling-circle’ amplification to produce large quantities of concatameric DNA that is then processed to create closed linear double-stranded DNA by enzymatic digestion. This novel form of DNA, Doggybone™ DNA (dbDNA™), is structurally distinct from plasmid DNA. Here we compare lentiviral vectors production from dbDNA™ and plasmid DNA. Lentiviral vectors were administered to neonatal mice via intracerebroventricular fi 1234567890();,: 1234567890();,: injection. Luciferase expression was quanti ed in conscious mice continually by whole-body bioluminescent imaging. We observed long-term luciferase expression using dbDNA™-derived vectors, which was comparable to plasmid-derived lentivirus vectors. Here we have demonstrated that functional lentiviral vectors can be produced using the novel dbDNA™ configuration for delivery in vitro and in vivo. Importantly, this could enable lentiviral vector packaging of complex DNA sequences that have previously been incompatible with bacterial propagation systems, as dbDNA™ technology could circumvent such restrictions through its phi29-based rolling-circle amplification. -
BMC Genomics Biomed Central
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central BMC Genomics BioMed Central Research article Open Access Comparative analysis of dinoflagellate chloroplast genomes reveals rRNA and tRNA genes Adrian C Barbrook*1, Nicole Santucci2, Lindsey J Plenderleith1, Roger G Hiller3 and Christopher J Howe1 Address: 1Department of Biochemistry, University of Cambridge, Downing Site, Tennis Court Road, Cambridge, CB2 1QW, UK, 2Children's Medical Research Institute, 214 Hawkesbury Road, Westmead, Sydney, NSW 2145, Australia and 3Department of Biological Sciences, Macquarie University, Sydney, NSW 2109, Australia Email: Adrian C Barbrook* - [email protected]; Nicole Santucci - [email protected]; Lindsey J Plenderleith - [email protected]; Roger G Hiller - [email protected]; Christopher J Howe - [email protected] * Corresponding author Published: 23 November 2006 Received: 23 June 2006 Accepted: 23 November 2006 BMC Genomics 2006, 7:297 doi:10.1186/1471-2164-7-297 This article is available from: http://www.biomedcentral.com/1471-2164/7/297 © 2006 Barbrook et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Peridinin-containing dinoflagellates have a highly reduced chloroplast genome, which is unlike that found in other chloroplast containing organisms. Genome reduction appears to be the result of extensive transfer of genes to the nuclear genome. -
Mitochondrial Minicircle DNA Supports Plasmid Replication and Maintenance in Nuclei of Trypanosoma Brucei
Proc. Natd. Acad. Sci. USA Vol. 91, pp. 5962-5966, June 1994 Biochemistry Mitochondrial minicircle DNA supports plasmid replication and maintenance in nuclei of Trypanosoma brucei STAN METZENBERG AND NINA AGABIAN* Intercampus Program in Molecular Parasitology, University of California - San Francisco, San Francisco, CA 94143-1204 Communicated by Anthony Cerami, February 25, 1994 (receivedfor review December 14, 1993) ABSTRACT In a search for trypanosome DNA sequences ing a shuttle vector that would allow the maintenance of that permit replication and stable maintenance of extrachro- multiple extrachromosomal copies ofa transfected sequence. mosomal elements, a 1-kilobase-pair (kbp) fragment from a By introducing random fiagments oftotal T. bruceiDNA into m ondrial kinetlst DNA (kDNA) micircie ofTrypano- a vector carrying a hygromycin-resistance gene, a mitochon- soma brucei was Isolated and characterized. The plasmid drial DNA element was identifiedt that permits plasmid pTbo-l, carrying the kDNA element, Is maintained in T. brucei replication and maintenance in the nuclei of T. brucei. The as a supercoiled concatemer contining approimatey seven to plasmid is maintained stably under continuous drug selection nine pTbo-1 monomer units (5.6 kbp each) in a head-to-tail as a supercoiled head-to-tail concatemer composed of ap- orientation. The cocater Is found In approximately one proximately eight monomer units. A second kDNA minicir- copy per cell when procydlic tyanosomes are cultur in the cle element, chosen at random and similarly tested, also presence of 100 jug of hyomycin per ml; however, in the permits autonomous replication. These findings suggest that absence Ofcontinuous hygromycin selection, the plasmid is lost minicircles may have the interesting capability of engender- from the population with a i,1otapproximately 8.7 days (17 cell ing DNA replication in both the mitochondrion and nucleus.